Join Our Team

We believe in doing good and thorough science, through which we aim to deliver safe and efficacious biosimilars for treating debilitating diseases.

Our endeavour is to create a meaningful difference in people’s health and lives. Our employees are integral to this vision, and we believe that everyone who comes on-board will be provided with an opportunity to express and excel in their careers.

We are always on the lookout for passionate, driven, and experienced individuals who are willing to partner with us on this exciting journey towards “Curing people and Healing lives”.

Our Values

Business Care

Operational Excellence

Stakeholder Orientation

Quality and Innovation

People Care

Fairness, Humility and Respect

Teamwork and Synergy

Applied Learning

Organisational Care

Accountability

Integrity

Achievement

3 Openings

Head – Upstream Process Development (R&D)

Hyderabad, India

Application deadline 31.12.2023

Head – Downstream Process Development (R&D)

Hyderabad, India

Application deadline 31.12.2023

Lead – Technology Transfer

Hyderabad, India

Application deadline 31.12.2023

1-3 of 3 items

Latest News

CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar
Press Release

15 March 24

CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar

Read More
Auro Peptides completes US FDA inspection with zero observations
Press Release

17 February 24

Auro Peptides completes US FDA inspection with zero observations

Read More
CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India
Press Release

17 January 24

CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India

Read More
CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector
Press Release

20 November 23

CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector

Read More
CuraTeQ Biologics to market Ustekinumab biosimilar to treat Crohn’s disease, arthritis
Press Release

10 July 23

CuraTeQ Biologics to market Ustekinumab biosimilar to treat Crohn’s disease, arthritis

Read More
CuraTeQ Biologics announces positive Phase-3 results for Trastuzumab biosimilar
Press Release

05 July 23

CuraTeQ Biologics announces positive Phase-3 results for Trastuzumab biosimilar

Read More
Aurobindo Pharma arm CuraTeQ expands scope of biosimilars distribution pact with Orion
Press Release

12 January 22

Aurobindo Pharma arm CuraTeQ expands scope of biosimilars distribution pact with Orion

Aurobindo Pharma on Tuesday said its subsidiary CuraTeQ Biologics has expanded the scope…

Read More
Aurobindo Pharma forays into biosimilars development
Press Release

12 February 17

Aurobindo Pharma forays into biosimilars development

Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar...

Read More